CTOs on the Move

Alzheon

www.alzheon.com

 
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.alzheon.com
  • 111 Speen Street Suite 306
    Framingham, MA USA 01701
  • Phone: 508.861.7709

Executives

Name Title Contact Details

Funding

Alzheon raised $47M on 08/20/2020

Similar Companies

Contextual Genomics

Transforming cancer care with data driven medicine

Folio Conversant

Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.

Teewinot Life Sciences Corp

Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology. Teewinot has also developed patent protected cannabinoid formulation technology all with the goal of improving human therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids. We are an industry leader in support of advancing medical research and product development. Teewinot`s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines.

Regado Biosciences

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.

MindMaze

MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.